背景介绍 IDO1/2 and TDO overexpression in tumor cells promotes tryptophan depletion in the microenvironment, resulting in suppression of the T-cell mediated immune response. IDO1/2 and TDO catalyze the breakdown of tryptophan into kynurenine, and KMO plays a key role in that pathway, hydroxylating kynurenine into 3-hydroxykynurenine. KMO is required for the synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist involved in axonal targeting, synaptogenesis and apoptosis during brain development. KMO activity has been linked to Huntington's (HD) and Alzheimer's diseases, and research shows that KMO inhibitors can improve the lifespan of Huntington's disease mice. In addition to being a therapeutic target for neurological disorders, elevated KMO also is an indicator of renal and hepatocellular carcinoma, suggesting KMO may have value as a prognostic biomarker. 产品介绍 The Kynurenine 3-Monooxygenase (KMO) Inhibitor Screening Assay Kit is designed to measure human KMO enzyme inhibition. The kit comes in a convenient format, with enough reaction solution and enzyme to perform a total of 400 reactions. The KMO Inhibitor Screening Assay Kit is simple to use. Recombinant hKMO is mixed with inhibitors and the reaction is initiated through addition of the substrates NADPH and L-Kynurenine. After a room temperature incubation, activity is determined by measuring the absorption of the reaction product at λ=412 nm. The UV absorption signal correlates with the amount of NADPH remaining in the reaction.